S&P 500
(0.31%) 5 115.88 points
Dow Jones
(0.31%) 38 358 points
Nasdaq
(0.35%) 15 983 points
Oil
(-0.88%) $83.11
Gas
(5.77%) $2.03
Gold
(0.36%) $2 355.70
Silver
(0.48%) $27.67
Platinum
(4.01%) $959.10
USD/EUR
(-0.22%) $0.933
USD/NOK
(-0.38%) $10.98
USD/GBP
(-0.54%) $0.796
USD/RUB
(1.69%) $93.43

リアルタイムの更新: Biomarin Pharmaceutical [BMRN]

取引所: NASDAQ セクター: Healthcare 産業: Biotechnology
BUY
66.00%
return 7.03%
SELL
34.69%
return 15.62%
最終更新日時30 4月 2024 @ 01:40

2.69% $ 83.09

売る 186 min ago

@ $82.07

発行日: 29 4月 2024 @ 22:33


リターン: 1.25%


前回のシグナル: 4月 26 - 04:29


前回のシグナル: 買う


リターン: -0.76 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:40):
Profile picture for Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease...

Stats
本日の出来高 559 600
平均出来高 1.55M
時価総額 15.77B
EPS $0 ( 2024-04-24 )
次の収益日 ( $0.610 ) 2024-07-29
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 78.39
ATR14 $1.428 (1.72%)
Insider Trading
Date Person Action Amount type
2024-04-12 Bienaime Jean Jacques Buy 20 000 Common Stock
2024-04-11 Bienaime Jean Jacques Sell 20 000 Common Stock
2024-04-12 Bienaime Jean Jacques Sell 20 000 Common Stock
2024-04-11 Bienaime Jean Jacques Sell 20 000 Stock Option (Right to Buy Common Stock)
2024-04-12 Bienaime Jean Jacques Sell 20 000 Stock Option (Right to Buy Common Stock)
INSIDER POWER
25.84
Last 93 transactions
Buy: 972 265 | Sell: 563 201

ボリューム 相関

長: 0.90 (strong)
短: -0.30 (neutral)
Signal:(53) Neutral

Biomarin Pharmaceutical 相関

10 最も正の相関
MMAC0.923
RMRM0.916
FREQ0.89
ABST0.889
IMPL0.889
SGBX0.887
TTOO0.887
INFI0.885
SBBP0.884
CFV0.884
10 最も負の相関
APOP-0.956
ICON-0.907
RDUS-0.893
MIND-0.88
TRMD-0.879
WRLD-0.878
SYKE-0.875
SOUN-0.873
MGTX-0.873
FEYE-0.869

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Biomarin Pharmaceutical 相関 - 通貨/商品

The country flag 0.13
( neutral )
The country flag 0.76
( moderate )
The country flag 0.00
( neutral )
The country flag 0.42
( neutral )
The country flag -0.19
( neutral )
The country flag -0.11
( neutral )

Biomarin Pharmaceutical 財務諸表

Annual 2023
収益: $2.42B
総利益: $1.84B (76.15 %)
EPS: $0.890
FY 2023
収益: $2.42B
総利益: $1.84B (76.15 %)
EPS: $0.890
FY 2022
収益: $2.10B
総利益: $1.61B (76.92 %)
EPS: $0.760
FY 2021
収益: $1.85B
総利益: $1.38B (74.52 %)
EPS: $-0.354

Financial Reports:

No articles found.

Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。